Indicators of immunogenicity of influenza vaccine in HIV-infected patients seronegative to influenza virus


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The immune response to standard scheme of seasonal vaccination against influenza was evaluated in HIV-infected patients without specific antibodies to influenza virus before vaccination. Titers of hemagglutinating antibodies to antigens of influenza virus A (H1N1), A (H3N2) and B were detected in standard agglutination inhibition test: before vaccination (day 0) and after it (on 21th and 150th days). Coefficient of seroconversion varied from 1.6to 2.3, seroconversion rate varied from 0to 25%); seroprotection rate - from 67% to A (H1N1) to 100% to A (H3N2) and B. Titer of antibodies detected on day 21 retained in all cases up to day 150 after vaccination. The minimal protective level of antibodies (1/40) was detected in the majority of vaccinated persons, including the at least fourfold increase of it in patients with CD4-cells level more than 350/pl.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Rafael’ Yapparov

Republican center for prevention and control of AIDS and infectious diseases

Email: rafdok@yandex.ru
chief doctor, infectiologist

Dmitry Lioznov

Research Institute of Influenza; Pavlov First State Medical University

Email: dlioznov@yandex.ru
MD, deputy director for science; head of the Department Of infectious diseases and epidemiology

Elena Karnaukhova

Pavlov First State Medical University

Email: elena_yk@list.ru
PhD, assistant professor of the Department of infectious diseases and epidemiology

Timofey Galankin

Pavlov First State Medical University

Email: galankint@gmail.com
PhD, head of the laboratory of pharmacoepidemiology and pharmacocinetics

Tamara Antonova

Pavlov First State Medical University

Email: antonovatv28@yandex.ru
MD, professor, professor of the Department of knfectious diseases and epidemiology

Әдебиет тізімі

  1. Методические рекомендации по диагностике и лечению гриппа. Министерство здравоохранения Российской Федерации. Москва, 2016. URL: https://petrsu.ru/files/user/fdbd9903df09bb6f04f397450a13732b/Recom_Flu.pdf [Methodological recommendations for diagnostics and treatment and treatment of grippe. Ministry of Healthcare of Russian Federation. Moscow, 2016. URL: https://petrsu.ru/files/user/fdbd9903df09bb6f04f397450a13732b/Recom_Flu.pdf]
  2. Рекомендации Европейского регионального бюро ВОЗ по вакцинации против гриппа в зимний сезон 2016-2017 гг. URL: http://www.euro.who.int/ data/assets/pdf_file/0004/321844/recommendations-influenza-vaccination-2016-2017-winterseason-ru.pdf [Recommendations of the European regional WHO buro concerning vaccination against grippe in winter season of 2016- 2017. URL: http://www.euro.who.int/ data/assets/pdf_file/0004/321844/recommendations-influenza-vaccination- 2016-2017-winter-season-ru.pdf]
  3. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. 2001;161:441-6.
  4. Zbinden D., Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy. 2014;6(2):131-9.
  5. Remschmidt C., Wichmann O., Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine. 2014;32(43):5585-92.
  6. The Australian immunization handbook. 10th ed. 2013:158.
  7. Ceravolo A., Orsi A., Parodi V. et al. Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. J. Prev. Med. Hyg. 2013;54:1-10.
  8. Crum-Cianflone N.F., Wallace M.R. Vaccination in HIV-infected adults. AIDS Patient Care STDS. 2014;28(8):397-410.
  9. Crum-Cianflone N.F., Sullivan E. Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect. Dis. Ther. 2017;6(3):303-31.
  10. Методы определения качества иммунобиологических препаратов для профилактики гриппа. Методические указания МУ 3.3.2.1758-03. - М., 2003. [Methods of determination of the quality of immunobiological medicaments for grippe prevention. Methodical guidelines of MU 3.3.2.1758-03. - М., 2003.]
  11. Concept Paper on the Revision of the CPMP/BWP Note for Guidance on Harmonization of Requirements for influenza Vaccines (CPMP/BWP/214/96). London, 31 May, 2001 / CPMP/EWP/1045/01.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2018